The role of bystander effects in the an hypoxia-activated prodrug PR-104

被引:42
|
作者
Foehrenbacher, Annika [1 ]
Patel, Kashyap [1 ]
Abbattista, Maria R. [1 ]
Guise, Chris P. [1 ]
Secomb, Timothy W. [2 ]
Wilson, William R. [1 ]
Hicks, Kevin O. [1 ]
机构
[1] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[2] Univ Arizona, Dept Physiol, Tucson, AZ 85721 USA
来源
FRONTIERS IN ONCOLOGY | 2013年 / 3卷
关键词
anticancer prodrugs; hypoxia-activated prodrugs; PR-104; bystander effect; extravascular drug transport; multicellular layers; pharmacokinetic/pharmacodynamic modeling; NADPH:cytochrome P450 oxidoreductase;
D O I
10.3389/fonc.2013.00263
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of prodrugs in tumors (e.g., by bioreduction in hypoxic zones) has the potential to generate active metabolites that can diffuse within the tumor microenvironment. Such "bystander effects" may offset spatial heterogeneity in prodrug activation but the relative importance of this effect is not understood. Here, we quantify the contribution of bystander effects to antitumor activity for the first time, by developing a spatially resolved pharmacokinetic/pharmacodynamic (SR-PK/PD) model for PR-104, a phosphate ester pre-prodrug that is converted systemically to the hypoxia-activated prodrug PR-104A. Using Green's function methods we calculated concentrations of oxygen, PR-104A and its active metabolites, and resultant cell killing, at each point of a mapped three-dimensional tumor microregion. Model parameters were determined in vitro, using single cell suspensions to determine relationships between PR-104A metabolism and clonogenic cell killing, and multicellular layer (MCL) cultures to measure tissue diffusion coefficients. LC-MS/MS detection of active metabolites in the extracellular medium following exposure of anoxic single cell suspensions and MCLs to PR-104A confirmed that metabolites can diffuse out of cells and through a tissue-like environment.The SR-PK/PD model estimated that bystander effects contribute 30 and 50% of PR-104 activity in SiHa and HCT116 tumors, respectively. Testing the model by modulating PR-104A-activating reductases and hypoxia in tumor xenografts showed overall clonogenic killing broadly consistent with model predictions. Overall, our data suggest that bystander effects are important in PR-104 antitumor activity, although their reach may be limited by macroregional heterogeneity in hypoxia and reductase expression in tumors. The reported computational and experimental techniques are broadly applicable to all targeted anticancer prodrugs and could be used to identify strategies for rational prodrug optimization.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The Role of Bystander Effects in the Anti-tumour Activity of the Hypoxia-activated Prodrug PR-104a
    Foehrenbacher, A.
    Abbattista, M. R.
    Secomb, T. W.
    Hicks, K. O.
    Wilson, W. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S237 - S237
  • [2] Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program
    Houghton, Peter J.
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Phelps, Doris
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Wozniak, Amy W.
    Gu, Yongchuan
    Wilson, William R.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2011, 57 (03) : 443 - 453
  • [3] Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104
    Benito, Juliana
    Shi, Yuexi
    Szymanska, Barbara
    Carol, Hernan
    Bohem, Ingrid
    Lu, Hongbo
    Konoplev, Sergej
    Fang, Wendy
    Kornblau, Steven M.
    Zweidler-McKay, Patrick
    Wilson, William
    Campana, Dario
    Borthakur, Gautam
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Shpall, Elizabeth J.
    Thomas, Deborah A.
    Jordan, Craig T.
    Lock, Richard B.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2010, 116 (21) : 379 - 380
  • [4] Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
    Benito, Juliana
    Shi, Yuexi
    Szymanska, Barbara
    Carol, Hernan
    Boehm, Ingrid
    Lu, Hongbo
    Konoplev, Sergej
    Fang, Wendy
    Zweidler-McKay, Patrick A.
    Campana, Dario
    Borthakur, Gautam
    Bueso-Ramos, Carlos
    Shpall, Elizabeth
    Thomas, Deborah A.
    Jordan, Craig T.
    Kantarjian, Hagop
    Wilson, William R.
    Lock, Richard
    Andreeff, Michael
    Konopleva, Marina
    PLOS ONE, 2011, 6 (08):
  • [5] Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial
    Patel, K.
    Gu, Y.
    Hicks, K. O.
    Atwell, G. J.
    Denny, W. A.
    Jameson, M. B.
    Rischin, D.
    Pegram, M.
    Gutheil, J. C.
    Wilson, W. R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 84 - 84
  • [6] A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors
    Jameson, M. B.
    Rischin, D.
    Pegram, M.
    Gutheil, J. C.
    Patterson, A.
    Denny, W.
    Wilson, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models
    Singleton, R. S.
    Pullen, S. M.
    Ferry, D. M.
    Guise, C. P.
    Patterson, A. V.
    Wilson, W. R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 151 - 151
  • [8] A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug administered on a weekly schedule in patients with solid tumors
    Melink, T. J.
    Jameson, M. B.
    McKeage, M. J.
    Gutheil, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Induction of DNA damage and repair responses by the hypoxia-activated prodrug PR-104.
    Douglas, RS
    Patterson, AV
    Yang, S
    Wilson, WR
    Siim, BG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8973S - 8974S
  • [10] Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry
    Patel, Kashyap
    Lewiston, David
    Gu, Yongchuan
    Hicks, Kevin O.
    Wilson, William R.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 856 (1-2): : 302 - 311